Table 2. Outcomes after hematopoietic... | American Society of Hematology

Table 2.

Outcomes after hematopoietic cell transplantation (grouped by rejection status and diagnoses)

UPN	Diagnosis	% donor CD3⁺		Rejection	DLI	GVHD		Survival, days	Summary of outcome as of 4/1/00
UPN	Diagnosis	Day 28	Day 56	Rejection	DLI	Acute (grade)	Chronic	Survival, days	Summary of outcome as of 4/1/00
UL 607^2-153	ALL-REL3	85	100		Yes^*	I		356^2-155	CR → REL → chemo/DLI → CR → Aspergillus
577^2-153	MF-AML-IF	84	85			III	Lim-S	> 621	CR
FH 14241^2-154	AML-aplasia	85	95			0	Ext-S, G^‡	> 549	CR
13461^2-153	AML-CR1	46	43		Yes × 2	II^†	Ext-S	> 759	Rel → chemo → CR → DLI → REL → chemo
14560^2-159	AML-CR1	40	99		Yes	0		> 473	CR
UL 646^2-153	AML-CR1	60	NE		Yes^*	II^†	Lim-S	> 341	Rel → DLI → CR → Rel → chemo/DLI → CR
627^2-159	AML-CR1	NE	NE			0		> 410	CR
636^2-159	AML-CR1	58	63			III	Lim-S	> 383	CR
UL 616^2-159	AML-CR2	55	50		Yes^*	0		172^2-155	Rel → PD
FH 13361^2-153	AML-CR3	50	90		Yes^*	II	Ext-S, G	168^2-155	Rel × 2 → DLI → CR mucor infection
SU 1857^2-153	AML-IF	50	NE			0	NE	38^2-155	PD → conventional BMT
FH 12914^2-153	CLL-REL2	100	100			II	Ext-S, O^‡	361^2-155	MCR Pneumococcal sepsis
SU 1879^2-153	CLL-PR2	56	86			III	Ext-S, G	> 528	MCR
FH 14587^2-159	CLL-REF	10	20			0	Ext-S, L, O	> 368	PR
14586^2-159	CLL-REF	90	80		Yes^*	II	Ext-S, L	244^2-155	PD
SU 2028^2-159	CLL-PR2	30	25		Yes^*	0		> 375	PR → PD
FH 14322^2-159	CLL-REF	65	95			I	Ext-E, O, S	> 319	MCR
14627^2-159	CLL-REF	71	96			III	Ext-L, O, S	> 325	CR
UL 596^2-153	CML-AP	79	95		Yes^*	II^†	Lim-S	> 530	MCR
UL 605^2-153	CML-CP	27	32			0	Lim-S	> 488	MCR
FH 14214^2-159	CML-CP	45	50			II	Ext-O, S	> 393	MCR
UL 634^2-159	CML-CP	43	70			I	Lim-O	> 390	MCR
FH 14726^2-159	CML-CP^2-160	100	95			II	Ext-E, G, L, O, S	> 368	MCR
SU 1955^2-153	HD-CR2	60	90		Yes × 2	0		164^2-155	PD
FH 13817^2-159	HD-PR	99	99			II	Ext-E, G, O, S	> 464	CR
14226^2-159	HD-REF	59	92		Yes^*	II	Ext-S	> 444	CR → Rel → XRT/chemo + DLI → PR
14692^2-159	HD-REF	70	90		Yes^*	II^†	NE	159^2-155	PD → Aspergillus infection
13527^2-159	MM-PR	99	97			II	Ext-E, O, S	> 416	CR
13922^2-159	MM-PR	83	94		Yes	0		> 417	CR^2-164
11924^2-159	MM-PR	94	97			0		> 473	CR^2-164
13541^2-159	MM-REF	98	100			II	NE	91^2-155	PD
14274^2-159	MM-REF	90	95			II	Ext-G, S	> 310	CR
UL 625^2-159	MM-REF	100	NE			III	NE	54^2-155	PR. Pneumonia, multiorgan failure
FH 14224^2-159	NHL-REF	88	100			II	NE	64^2-155	CR. Intracranial hemorrhage
14413^2-159	WM-REF	58	62			II	Ext-E, O, S	> 380	SD
14658^2-159	WM-REF	85	90		Yes × 2^*	0	Lim-S, O	> 333	SD
UL 644^2-159	AML-CR1	20	5	Yes	Yes	0		133^2-155	Rel → 2nd NMHCT → engrafted → PD
14284^2-159	CLL-PR	19	24	Yes	Yes	0		> 376	PD
14091^2-153	CML-AP	40	30	Yes	Yes	I		227^2-155	PD → Conventional BMT
SU 2000^2-159	CML-AP	25	30	Yes	Yes	0		407^2-155	PD → 2nd NMHCT → rejected → PD
SU 1948^2-153	CML-CP	60	30	Yes	Yes	0		> 501	PD → 2nd NMHCT → rejected
UL 622^2-159	CML-CP	10	8	Yes	Yes	0		> 341	PD
FH 13009^2-153	MDS-RAEB-T	40	35	Yes	Yes	0		183^2-155	PD + liver cirrhosis
13246^2-153	MM-REF	43	35	Yes	Yes	0		> 731	PD psoriasis in CR
13230^2-153	MM-PR	15	5	Yes	Yes	0		> 751	REL

UPN	Diagnosis	% donor CD3⁺		Rejection	DLI	GVHD		Survival, days	Summary of outcome as of 4/1/00
UPN	Diagnosis	Day 28	Day 56	Rejection	DLI	Acute (grade)	Chronic	Survival, days	Summary of outcome as of 4/1/00
UL 607^2-153	ALL-REL3	85	100		Yes^*	I		356^2-155	CR → REL → chemo/DLI → CR → Aspergillus
577^2-153	MF-AML-IF	84	85			III	Lim-S	> 621	CR
FH 14241^2-154	AML-aplasia	85	95			0	Ext-S, G^‡	> 549	CR
13461^2-153	AML-CR1	46	43		Yes × 2	II^†	Ext-S	> 759	Rel → chemo → CR → DLI → REL → chemo
14560^2-159	AML-CR1	40	99		Yes	0		> 473	CR
UL 646^2-153	AML-CR1	60	NE		Yes^*	II^†	Lim-S	> 341	Rel → DLI → CR → Rel → chemo/DLI → CR
627^2-159	AML-CR1	NE	NE			0		> 410	CR
636^2-159	AML-CR1	58	63			III	Lim-S	> 383	CR
UL 616^2-159	AML-CR2	55	50		Yes^*	0		172^2-155	Rel → PD
FH 13361^2-153	AML-CR3	50	90		Yes^*	II	Ext-S, G	168^2-155	Rel × 2 → DLI → CR mucor infection
SU 1857^2-153	AML-IF	50	NE			0	NE	38^2-155	PD → conventional BMT
FH 12914^2-153	CLL-REL2	100	100			II	Ext-S, O^‡	361^2-155	MCR Pneumococcal sepsis
SU 1879^2-153	CLL-PR2	56	86			III	Ext-S, G	> 528	MCR
FH 14587^2-159	CLL-REF	10	20			0	Ext-S, L, O	> 368	PR
14586^2-159	CLL-REF	90	80		Yes^*	II	Ext-S, L	244^2-155	PD
SU 2028^2-159	CLL-PR2	30	25		Yes^*	0		> 375	PR → PD
FH 14322^2-159	CLL-REF	65	95			I	Ext-E, O, S	> 319	MCR
14627^2-159	CLL-REF	71	96			III	Ext-L, O, S	> 325	CR
UL 596^2-153	CML-AP	79	95		Yes^*	II^†	Lim-S	> 530	MCR
UL 605^2-153	CML-CP	27	32			0	Lim-S	> 488	MCR
FH 14214^2-159	CML-CP	45	50			II	Ext-O, S	> 393	MCR
UL 634^2-159	CML-CP	43	70			I	Lim-O	> 390	MCR
FH 14726^2-159	CML-CP^2-160	100	95			II	Ext-E, G, L, O, S	> 368	MCR
SU 1955^2-153	HD-CR2	60	90		Yes × 2	0		164^2-155	PD
FH 13817^2-159	HD-PR	99	99			II	Ext-E, G, O, S	> 464	CR
14226^2-159	HD-REF	59	92		Yes^*	II	Ext-S	> 444	CR → Rel → XRT/chemo + DLI → PR
14692^2-159	HD-REF	70	90		Yes^*	II^†	NE	159^2-155	PD → Aspergillus infection
13527^2-159	MM-PR	99	97			II	Ext-E, O, S	> 416	CR
13922^2-159	MM-PR	83	94		Yes	0		> 417	CR^2-164
11924^2-159	MM-PR	94	97			0		> 473	CR^2-164
13541^2-159	MM-REF	98	100			II	NE	91^2-155	PD
14274^2-159	MM-REF	90	95			II	Ext-G, S	> 310	CR
UL 625^2-159	MM-REF	100	NE			III	NE	54^2-155	PR. Pneumonia, multiorgan failure
FH 14224^2-159	NHL-REF	88	100			II	NE	64^2-155	CR. Intracranial hemorrhage
14413^2-159	WM-REF	58	62			II	Ext-E, O, S	> 380	SD
14658^2-159	WM-REF	85	90		Yes × 2^*	0	Lim-S, O	> 333	SD
UL 644^2-159	AML-CR1	20	5	Yes	Yes	0		133^2-155	Rel → 2nd NMHCT → engrafted → PD
14284^2-159	CLL-PR	19	24	Yes	Yes	0		> 376	PD
14091^2-153	CML-AP	40	30	Yes	Yes	I		227^2-155	PD → Conventional BMT
SU 2000^2-159	CML-AP	25	30	Yes	Yes	0		407^2-155	PD → 2nd NMHCT → rejected → PD
SU 1948^2-153	CML-CP	60	30	Yes	Yes	0		> 501	PD → 2nd NMHCT → rejected
UL 622^2-159	CML-CP	10	8	Yes	Yes	0		> 341	PD
FH 13009^2-153	MDS-RAEB-T	40	35	Yes	Yes	0		183^2-155	PD + liver cirrhosis
13246^2-153	MM-REF	43	35	Yes	Yes	0		> 731	PD psoriasis in CR
13230^2-153	MM-PR	15	5	Yes	Yes	0		> 751	REL

GVHD indicates graft-versus-host disease; DLI, donor lymphocyte infusion; NE, not evaluable; PD, progressive disease; BMT, bone marrow transplantation; MCR, molecular remission; XRT, radiation therapy; SD, stable disease; NMHCT, nonmyeloablative hematopoietic cell transplantation; TBI, total-body irradiation; MMF, mycophenolate mofetil; and CSP, cyclosporine. For other abbreviations, see Table 1.

Indicates initial DLI given for relapse or progressive disease.

†

Indicates GVHD first occurred after DLI.

‡

Indicates GVHD resolved; patient off immunosuppressive therapy. GVHD extent: Lim indicates limited GVHD; Ext, extensive GVHD. GVHD organ involvement: E indicates eyes; G, gastrointestinal; L, liver; O, oral; S, skin.

F2-153

Cohort 1: CSP scheduled day −1 to +35.

F2-155

Patient died.

F2-154

CSP taper delayed to day +100 to prevent GVHD because of active fungal infection.

F2-159

Cohort 2: CSP scheduled day −1 to +56.

F2-160

Patient 14726 received fludarabine 30 mg/m² × 3 in addition to TBI/MMF/CSP.

F2-164

Trace monoclonal protein detected intermittently by immunofixation after CR was achieved.

View Large

This Feature Is Available To Subscribers Only